Notable Price Action: Alnylam Pharmaceuticals, Inc.’s Trend Up, Especially After Today’s Strong Session

Notable Price Action: Alnylam Pharmaceuticals, Inc.'s Trend Up, Especially After Today's Strong Session

The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a huge mover today! The stock increased 4.53% or $2.07 on November 23, hitting $47.72. About 1.10 million shares traded hands. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 33.63% since April 22, 2016 and is downtrending. It has underperformed by 39.04% the S&P500.
The move comes after 7 months positive chart setup for the $3.96 billion company. It was reported on Nov, 24 by Barchart.com. We have $49.15 PT which if reached, will make NASDAQ:ALNY worth $118.80M more.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 9. They expect $-1.35 EPS, down 26.17% or $0.28 from last year’s $-1.07 per share. After $-1.21 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 11.57% negative EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Out of 14 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 57% are positive. Alnylam Pharmaceuticals has been the topic of 30 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by FBR Capital on Tuesday, August 11. JMP Securities maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Wednesday, March 9 with “Market Outperform” rating. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Neutral” rating by Goldman Sachs on Thursday, October 6. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by Leerink Swann on Tuesday, May 3. JP Morgan downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Friday, August 7 to “Neutral” rating. The firm has “Overweight” rating by JP Morgan given on Friday, August 5. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Hold” rating given on Thursday, October 6 by Stifel Nicolaus. As per Wednesday, January 20, the company rating was initiated by Credit Suisse. Janney Capital initiated it with “Neutral” rating and $74 target price in Thursday, September 29 report. On Tuesday, February 16 the stock rating was maintained by Leerink Swann with “Outperform”.

According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”

Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.25, from 1.27 in 2016Q1. The ratio dropped, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Ibm Retirement Fund holds 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 7,559 shares. Daiwa Securities Gru last reported 0% of its portfolio in the stock. Jennison Associate Ltd Liability Com, a New York-based fund reported 975,425 shares. Federated Pa reported 10,561 shares or 0% of all its holdings. Aviva Public Limited Co holds 44,126 shares or 0.02% of its portfolio. Moreover, Hsbc Public has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 9,896 shares. Caisse De Depot Et Placement Du Quebec owns 10,200 shares or 0% of their US portfolio. Blackrock Invest Limited Com has 0% invested in the company for 54,056 shares. Invesco Limited accumulated 12,267 shares or 0% of the stock. Slate Path Cap Ltd Partnership holds 4.93% or 1.14 million shares in its portfolio. Moreover, Axa has 0.03% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 125,662 shares. Moreover, Signpost Cap Advsrs Lp has 1% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 34,365 shares. Mirae Asset Global Invs Ltd owns 11,074 shares or 0.02% of their US portfolio. Nomura Asset Mngmt Co Limited owns 8,000 shares or 0.01% of their US portfolio. British Columbia Inv Corp owns 14,377 shares or 0.01% of their US portfolio.

Insider Transactions: Since July 19, 2016, the stock had 1 insider purchase, and 1 sale for $918,262 net activity. Shares for $1.03 million were bought by PYOTT DAVID E I on Thursday, October 13. 30,151 shares with value of $1.95 million were sold by MARAGANORE JOHN on Tuesday, July 19.

More news for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were recently published by: Fool.com, which released: “Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data” on November 04, 2016. Fool.com‘s article titled: “Why Alnylam Pharmaceuticals, Inc. Took a 47.5% Dive in October” and published on November 07, 2016 is yet another important article.

ALNY Company Profile

Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment